Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.67 |
| ▸ | DPP8 | Q6V1X1 | 11/20 | 0.66 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.66 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.61 |
| ▸ | ACE | P12821 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | FAP | Q12884 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1071529 | 0.92 | DPP4 (0.67) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL10257540 | 0.87 | DPP4 (0.64) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL8325488 | 0.85 | DPP4 (0.70) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL2669515 | 0.85 | DPP4 (0.58) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL2662331 | 0.85 | DPP4 (0.58) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL12767539 | 0.84 | DPP4 (0.68) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL8243586 | 0.83 | DPP4 (0.67) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL5495348 | 0.83 | DPP4 (0.61) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL3389459 | 0.82 | DPP4 (0.67) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL8362732 | 0.82 | DPP4 (0.67) | DPP4DPP8DPP7DPP9ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101626-B2 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-7816364-B2 | GRP119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100190750-A1 | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20090270422-A1 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190750-A1 | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto | GPR119, GLP1R, GPR4 | DPP4 5/4885DPP8 35/4885DPP7 16/4885 |
| US-20090270422-A1 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | GPR119, GLP1R, GPR4 | DPP4 5/4885DPP8 35/4885DPP7 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.